ACTIVADOR TISULAR DEL PLASMINOGENO RECOMBINANTE PDF

Recombinant tissue plasminogen activator for the management of intracardiac thrombi in newborns. ISSN Introduction: The incidence of cardiac thrombi in newborns has increased with the use of central venous catheters. Thrombolysis with recombinant tissue plasminogen activator rTPA has been used as an alternative to heparin in life threatening giant thrombus and embolization. The aim of this study is to describe the response and complications related to the use of rTPA in the management of life- threatening cardiac thrombi in newborns.

Author:Vukinos Shakarn
Country:Malawi
Language:English (Spanish)
Genre:Video
Published (Last):7 February 2014
Pages:12
PDF File Size:3.10 Mb
ePub File Size:11.43 Mb
ISBN:369-1-39637-891-4
Downloads:5846
Price:Free* [*Free Regsitration Required]
Uploader:Dihn



Recombinant tissue plasminogen activator for the management of intracardiac thrombi in newborns. ISSN Introduction: The incidence of cardiac thrombi in newborns has increased with the use of central venous catheters. Thrombolysis with recombinant tissue plasminogen activator rTPA has been used as an alternative to heparin in life threatening giant thrombus and embolization. The aim of this study is to describe the response and complications related to the use of rTPA in the management of life- threatening cardiac thrombi in newborns.

Patients and method: The medical records of 8 newborn were reviewed in a retrospective study, of whom 7 were preterm with cardiac thrombi, and rTPA was used in all of them. Results: The patients included 4 males with a mean weight of gr.

The superior vena cava was the most frequent location, with a mean time of installation before the diagnosis of 12 days. Three patients received low molecular weight heparin prior to using rTPA. They received between 1 to 5 cycles with rTPA.

In 4 patients complete resolution of the thrombus was achieved in a mean of 3. Four patients had intracranial haemorrhage grade I, without sequelae at follow-up.

There were no deaths or embolism. Palavras-chave : Intracardiac thrombi; Neonatal thrombolysis; Recombinant tissue plasminogen activator.

Como citar este artigo.

BLAST VORTICISM PDF

2003, Número 2

It is edited by Dr. The Journal accepts works on basic as well applied research on any field of neurology. The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two receding years. CiteScore measures average citations received per document published. Read more. SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

ANABOLE STEROIDE 2010 PDF

activador de plasminógeno tisular recombinante

Introduction: Cancer patients have increased stroke risk from direct and indirect malignancy effects. Intravenous thrombolysis with recombinant tissue plasminogen activator rtPA is standard medical treatment for acute ischemic stroke AIS. Conclusion: Severe haemorrhagic complications, potentiated by rtPA, carry increased risk of morbidity and mortality. Active cancer should not be considered an absolute contraindication to rtPA use. Risk of complications and life expectancy should be assessed when making this decision. Title: Seguridad y efectividad del rtPA en el ictus isquemico agudo en pacientes con cancer activo: estudio de casos y controles. Los pacientes con cancer tiene un mayor riesgo de ictus debido a los efectos malignos directos e indirectos.

FILOSOFIA DEL DERECHO GARCIA MAYNEZ PDF

.

DIN EN 13725 PDF

.

Related Articles